Iontophoresis challenge for monitoring cardiovascular status

• US 20070118045A1
• Filed: 10/23/2006
• Published: 05/24/2007
• Est. Priority Date: 10/21/2005
• Status: Abandoned Application

• Current Assignee: Endothelix, Inc.
• Original Assignee: Endothelix, Inc.
• Inventors: O'Brien, Timothy, Johnson, Mark, Jamieson, Craig, Naghavi, Morteza
• Application Number:
  US11/585,781
• Publication Number:
  US 20070118045A1
• Time in Patent Office: Days
• US Class Current: 600/549
• CPC Class Codes: A61B 5/01 Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue clinical contact thermometers G01K13/20
• CPC Class Codes: A61B 5/02007 Evaluating blood vessel condition, e.g. elasticity, compliance

Abstract

Methods and apparatus are provided for determining individual vascular responses by employing iontophoresis to deliver vasoactive compounds to local area and determining resultant changes in blood flow by measuring changes in skin temperature as a correlate of local blood flow. The invention further provides methods and apparatus for assessing vascular reactivity in individuals under ambulatory conditions and relating stress responses to vascular reactivity.

Claims

1. A method of assessing vascular and/or neurovascular responsiveness in an individual comprising:

continuously measuring and recording skin temperature at a test location on an individual;

administering a vasostimulator compound by iontophoresis to the test location; and

determining vascular and/or neurovascular responsiveness on the basis of skin temperature changes in response to the vasoactive compound.

2. The method of claim 1, wherein the vasostimulator compound is an endothelium-dependent vasoactive compound.

3. The method of claim 2, wherein the endothelium-dependent vasostimulator compound comprises acetylcholine.

4. The method of claim 1, wherein the vasostimulator compound is an endothelium-independent vasoactive compound.

5. The method of claim 2, wherein the endothelium-independent vasostimulator compound comprises sodium nitroprusside.

6. The method of claim 1, further comprising administering a psychological stress inducer concomitant with determining responsiveness to the vasostimulator compound.

7. The method of claim 1, wherein the test location is selected from the group consisting of:

forearm, wrist, forehead and finger.

8. The method of claim 1, further comprising simultaneously and continuously measuring and recording a reactive hyperemia response induced in a vascular bed feeding the test location.

9. The method of claim 1, further comprising simultaneously measuring and recording additional physiologic parameters selected from the group consisting of:

pulse rate, blood pressure, galvanic response, blood oxygenation, and sweating.

10. The method of claim 1, where skin temperature is measured by a thermal potential difference using a thermocouple.

11. The method of claim 1, wherein the skin temperature is measured by an infrared detector.

12. A vascular and/or neurovascular function measurement device comprising:

a housing including an iontophoretic chamber adapted to store and deliver a charged vasostimulator e compound through skin of a patient; and

one or more temperature sensors mounted on the housing and adapted to detect changes in skin temperature in response to delivery of the vasostimulator compound.

13. The device of claim 12, wherein the temperature sensor is selected from the group consisting of:

thermocouples, thermopiles and infrared detectors.

14. The device of claim 12, further comprising a heating element.

15. The device of claim 12, further comprising a chemical sensor.

16. The device of claim 12, wherein the housing is dimensioned to be affixed flat to a skin surface.

17. The device of claim 12, wherein the housing is dimension to be worn as a ring.

18. A method of vascular and/or neurovascular function measurement comprising:

initiating monitoring of an inherent temperature of a mucosal surface;

administering a vasostimulator directly to the mucosal surface;

continuing to monitor any temperature change as a consequence of administration of the vasostimulator; and

determining vascular and/or neurovascular responsiveness on the basis of temperature changes in response to the vasostimulator.

19. The method of claim 18, wherein the monitoring is by contact thermal sensor.

20. The method of claim 18, wherein the monitoring is by digital infrared thermal imaging.

21. The method of claim 18, wherein the mucosal surface is selected from the group consisting of the:

eye mucosa, sublingual mucosa, intranasal mucosa, rectal mucosa, vaginal mucosal and urethral mucosa.